Back to Pulmonology
Pulmonologyv1987Evidence-Based

Manchester Score for Prognosis in Small Cell Lung Cancer

Predicts 2-year survival in patients with small cell lung cancer (SCLC) using six clinical and laboratory parameters. Stratifies patients into three prognostic groups (good, medium, poor) to guide treatment decisions and clinical management.

Clinical Input Parameters

mmol/L
Range: 110 — 160 mmol/L
mmol/L
Range: 10 — 40 mmol/L
points
Range: 0 — 100 points
Clinical Assessment
Awaiting Parameters
manchester score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Manchester Score for Prognosis in Small Cell Lung Cancer is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within pulmonology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Manchester Score = LDH points + Sodium points + Alkaline Phosphatase points + Bicarbonate points + Disease Stage points + Karnofsky Performance Status points. LDH >ULN (1 point), Na <132 mmol/L (1 point), ALP >1.5x ULN (1 point), HCO3 <24 mmol/L (1 point), Extensive stage (1 point), KPS ≤50 (1 point). Total score 0-1 = Good prognosis, 2-3 = Medium prognosis, 4-6 = Poor prognosis.

Clinical Pearls & Practice Notes

  • Developed from analysis of 407 small cell lung cancer patients treated between 1979-1985
  • 61 pre-treatment variables were initially evaluated through multiple regression analysis
  • Simple scoring system shows little loss of prognostic information compared to complex Cox analysis
  • Helps distinguish three distinct prognostic groups with clinically meaningful survival differences
  • Good prognostic group contains all long-term survivors from the original cohort
  • Poor prognostic group had no patients surviving longer than one year
  • Facilitates comparison between different treatment studies and research protocols
  • May assist in treatment decision-making and shared clinical decision-making discussions
  • Particularly useful for determining appropriateness of aggressive vs. palliative treatment approaches
  • Score developed during era when more prognostic information was requested by patients and physicians due to limited cure rates in SCLC

Evidence & Literature Citations

  1. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987 Jul 15;40(1):1-7. doi: 10.1002/ijc.2910400102.
  2. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol. 1995 May;13(5):1221-30. doi: 10.1200/JCO.1995.13.5.1221.
  3. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol. 1990 Sep;8(9):1563-74. doi: 10.1200/JCO.1990.8.9.1563.

Score Interpretation Ranges

Good Prognosis0 – 1 pts

Good prognostic group with best survival outcomes

Medium Prognosis2 – 3 pts

Intermediate prognostic group with moderate survival outcomes

Poor Prognosis4 – 6 pts

Poor prognostic group with worst survival outcomes

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.